EUVIMEDEUVIMED entdecken
BeobachtungsstudieKlinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY 4.0

The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness

Fabrizio Vernieri, Anna Ambrosini, Marco Bartolini, Sabina Cevoli, Gianluca Coppola, Florindo D'Onofrio, Roberto De Simone, Antonio Granato, Simona Guerzoni, Maria Pia Prudenzano, Innocenzo Rainero, Renata Rao und 3 weitere

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08504-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, 2025. Verfasst von Fabrizio Vernieri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neurosonology Unit, Fondazione Policlinico Campus Bio-Medico and Università Campus Bio-Medico di Roma, Rome, Italy. F.Vernieri@policlini…. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Teva Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Migraine burden encompasses social, economic, and functional burden; most notably in individuals with either chronic or high-frequency episodic migraine (CM, HFEM). This second interim sub-analysis of Italian participants with CM and HFEM enrolled in the PEARL study provides updated real-world evidence of fremanezumab use in Italian clinical practice for up to 12 months of treatment.

Methods

In this second interim sub-analysis, data were collected from a sub-population of participants enrolled in PEARL who were treated in Italian headache centers and had completed 12 months of fremanezumab treatment (data cut-off: 15 June 2023). The primary endpoint was the proportion of participants achieving a ≥ 50% reduction in monthly migraine days (MMD) during the 6-month period after fremanezumab initiation. Additional endpoints were assessed up to Month 12 and included mean change from baseline in average MMD. Safety was assessed through adverse events (AEs) reported.

Results

Overall, 343/354 participants enrolled in Italian headache centers (HFEM, 36.2%; CM, 63.8%) were included in the effectiveness analysis. Of those with data available, 61.2% of participants achieved a ≥ 50% reduction in average MMD during the 6-month period after fremanezumab initiation. Mean change from baseline (± standard deviation [SD]) in average MMD was − 8.2 ± 7.4 at Month 1 and − 8.9 ± 6.9 at Month 12. No new safety signals were observed.

Conclusion

Fremanezumab was effective and well tolerated in Italian clinical practice, with results in line with those previously reported for fremanezumab in a real-world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, MonoclonalHumansFemaleItalyMaleAdultMiddle AgedProspective StudiesTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

Calcitonin gene-related peptideFremanezumabMigraineMonoclonal antibodiesReal-world dataReal-world evidence

Substanzen

fremanezumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Headache and Neurosonology Unit, Fondazione Policlinico Campus Bio-Medico and Università Campus Bio-Medico di Roma, Rome, Italy. F.Vernieri@policlinicocampus.it.
  • Headache Unit, IRCCS Neuromed, Pozzilli, Italy.
  • Neurological Clinic, Marche Polytechnic University, Via Conca 1, Ancona, Italy.
  • Istituto delle Scienze Neurologiche di Bologna, Programma Cefalee e Algie Facciali, Bologna, Italy.
  • Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, ICOT, Latina, Italy.
  • Neurology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.

Förderung

  • Teva Pharmaceuticals

Zitieren

APA

Vernieri, F., Ambrosini, A., Bartolini, M., Cevoli, S., Coppola, G., D'Onofrio, F., De Simone, R., Granato, A., Guerzoni, S., Prudenzano, M. P., Rainero, I., Rao, R., Tassorelli, C., Kokturk, P., & Cepparulo, M. (2025). The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness. Neurological Sciences. https://doi.org/10.1007/s10072-025-08504-0

Vancouver

Vernieri F, Ambrosini A, Bartolini M, Cevoli S, Coppola G, D'Onofrio F, et al. The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness. Neurological Sciences. 2025. doi:10.1007/s10072-025-08504-0

BibTeX
@article{Vernieri2025,
  author = {Vernieri, Fabrizio and Ambrosini, Anna and Bartolini, Marco and Cevoli, Sabina and Coppola, Gianluca and D'Onofrio, Florindo and De Simone, Roberto and Granato, Antonio and Guerzoni, Simona and Prudenzano, Maria Pia and Rainero, Innocenzo and Rao, Renata and Tassorelli, Cristina and Kokturk, Pinar and Cepparulo, Mario},
  title = {The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08504-0}
}
Kostenlos starten →